Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death. In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death. In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk. Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death. COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients.

由于潜在的恶性肿瘤和治疗引起的免疫抑制，据推测患有癌症的患者发生严重 COVID-19 结局的风险增加。在 Gustave Roussy 癌症中心接受 COVID-19 治疗的前 178 名患者中，125 名（70.2%）住院，47 名（26.4%）出现临床恶化，31 名（17.4%）死亡。年龄超过 70 岁、吸烟状况、转移性疾病、细胞毒性化疗和最后一次就诊时东部肿瘤协作组评分≥2 是死亡风险增加的最强决定因素。在多变量分析中，东部肿瘤协作组评分仍然是唯一的死亡预测因子。相比之下，免疫疗法、激素疗法和靶向疗法并未增加临床恶化或死亡风险。生物标志物研究发现，C-反应蛋白和乳酸脱氢酶水平与临床恶化风险增加显着相关，而 C-反应蛋白和 D-二聚体水平与死亡风险增加相关。COVID-19 管理影响了肿瘤治疗策略，导致 41% 的患者中位延迟 20 天，30% 的患者调整治疗策略。